Unsupervised 3D Brain Anomaly Detection

TL;DR

This paper introduces a novel unsupervised 3D brain anomaly detection method using deep generative models, capable of identifying various brain abnormalities in volumetric medical images with high accuracy.

Contribution

It presents the first efficient 3D volumetric anomaly detection model combining a 3D GAN with refinement training, extending 2D models to handle complex brain imaging data.

Findings

Detects TBI abnormalities with ~75% AUC

Identifies artifacts and post-operative signs

Potential for large-scale anomaly labeling

Abstract

Anomaly detection (AD) is the identification of data samples that do not fit a learned data distribution. As such, AD systems can help physicians to determine the presence, severity, and extension of a pathology. Deep generative models, such as Generative Adversarial Networks (GANs), can be exploited to capture anatomical variability. Consequently, any outlier (i.e., sample falling outside of the learned distribution) can be detected as an abnormality in an unsupervised fashion. By using this method, we can not only detect expected or known lesions, but we can even unveil previously unrecognized biomarkers. To the best of our knowledge, this study exemplifies the first AD approach that can efficiently handle volumetric data and detect 3D brain anomalies in one single model. Our proposal is a volumetric and high-detail extension of the 2D f-AnoGAN model obtained by combining a state-of-the-art 3D GAN with refinement training steps. In experiments using non-contrast computed tomography images from traumatic brain injury (TBI) patients, the model detects and localizes TBI abnormalities with an area under the ROC curve of ~75%. Moreover, we test the potential of the method for detecting other anomalies such as low quality images, preprocessing inaccuracies, artifacts, and even the presence of post-operative signs (such as a craniectomy or a brain shunt). The method has potential for rapidly labeling abnormalities in massive imaging datasets, as well as identifying new biomarkers.